Vivos (RDGL) Net Cash Flow Growth (1y) (2011 - 2025)
Vivos (RDGL) Net Cash Flow Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.20 Bn | 175.91 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 128.87 Bn | 125.99 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 108.88 Bn | 99.66 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 68.33 Bn | 66.87 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 47.31 Bn | 43.64 Bn | 1.29 Bn | -564.44% |
| 6 | Dexcom | 28.65 Bn | 27.53 Bn | 750.30 Mn | -31.84% |
| 7 | GE HealthCare Technologies | 28.40 Bn | 26.11 Bn | 1.98 Bn | -394.13% |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - | - |
| 9 | Koninklijke Philips | 25.55 Bn | 22.42 Bn | 2.07 Bn | 76.43% |
| 10 | Vivos | 27.57 Mn | 26.01 Mn | -3,105.00 | -154.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -154.34% |
| Sep 30, 2025 | 9.44% |
| Jun 30, 2025 | -270.96% |
| Mar 31, 2025 | 575.28% |
| Dec 31, 2024 | 1,693.53% |
| Sep 30, 2024 | -138.89% |
| Jun 30, 2024 | 212.49% |
| Mar 31, 2024 | 24.58% |
| Dec 31, 2023 | 119.68% |
| Sep 30, 2023 | 25.11% |
| Jun 30, 2023 | -83.70% |
| Mar 31, 2023 | 23.59% |
| Dec 31, 2022 | 25.97% |
| Sep 30, 2022 | -58.90% |
| Jun 30, 2022 | 50.71% |
| Mar 31, 2022 | -123.90% |
| Dec 31, 2021 | -142.81% |
| Sep 30, 2021 | 23.87% |
| Jun 30, 2021 | -242.37% |
| Mar 31, 2021 | 10,558.09% |